infecti
diseas
major
threat
human
imper
develop
imag
tool
aid
studi
facilit
diagnosi
guid
treatment
alarm
rise
highli
virul
multidrugresist
pathogen
rapid
spread
lead
frequent
global
pandem
fear
bioterror
continu
lifethreaten
nosocomi
infect
hospit
remain
major
challeng
health
care
usa
worldwid
earli
diagnosi
rapid
monitor
essenti
appropri
manag
control
infect
tomograph
molecular
imag
enabl
rapid
noninvas
visual
local
monitor
molecular
process
deep
within
bodi
offer
sever
advantag
tradit
tool
use
studi
infecti
diseas
noninvas
longitudin
assess
could
streamlin
anim
studi
allow
uniqu
insight
diseas
pathogenesi
expedit
clinic
translat
new
therapeut
sinc
molecular
imag
alreadi
common
use
clinic
could
also
becom
valuabl
tool
clinic
studi
patient
care
public
health
enabl
precis
medicin
infecti
diseas
human
modern
era
increasingli
prone
virul
infect
select
dissemin
bsuper
bugsbi
overus
misus
antimicrobi
global
travel
rapid
spread
infect
increas
use
medic
proceduresimpl
cathet
immunosuppressivecanc
therapiesar
lead
lifethreaten
infect
grow
threat
human
american
develop
hospitalacquir
infect
result
death
usa
bacteria
notabl
enterobacteriacea
famili
clostridium
difficil
staphylococcu
aureu
pseudomona
aeruginosa
account
major
infect
similarli
viral
infect
influenza
caus
million
new
case
sever
thousand
death
annual
usa
burden
hospitalacquir
infect
substanti
higher
global
exampl
mycobacterium
tuberculosi
caus
agent
tuberculosi
tb
respons
million
new
case
death
alon
alarm
rise
multidrugresist
mdr
extens
drugresist
xdr
strain
well
hiv
coinfect
continu
fuel
epidem
global
travel
rapid
spread
infectionsswin
flu
sarscov
ebola
zika
virushav
led
sever
recent
global
pandem
final
sever
infecti
pathogen
eg
yersinia
pesti
caus
plagu
enterobacteriacea
famili
also
recogn
biothreat
agent
process
vivo
key
control
infect
therefor
world
molecular
imag
societi
made
commit
advanc
imag
tool
infecti
diseas
inflamm
creat
imag
infect
interest
group
ioiig
interest
group
task
mission
global
advanc
develop
new
imag
technolog
infecti
diseas
translat
effect
imag
tool
provid
uniqu
insight
diseas
mechan
enabl
drug
vaccin
develop
guid
treatment
benefit
patient
fig
part
effort
ioiig
organ
sever
session
world
molecular
imag
congress
wmic
includ
workshop
focus
imag
infect
inflamm
brought
togeth
individu
multipl
scientif
disciplin
highlight
latest
develop
field
addit
workshop
also
panel
discuss
challeng
fund
research
panelist
us
nation
institut
health
similar
workshop
plan
wmic
philadelphia
pa
focu
leverag
current
resourc
promot
collabor
clinic
translat
find
strategi
overcom
challeng
fund
research
emerg
field
rapid
accur
diagnosi
local
infect
essenti
effect
earli
intervent
appropri
manag
howev
tradit
diagnost
tool
name
microscopi
microbiolog
molecular
techniqu
depend
upon
sampl
suspect
site
infect
often
blindli
perform
assay
time
consum
major
advanc
made
applic
molecular
techniqu
nucleic
acid
amplif
naa
deep
sequenc
matrixassist
laser
desorptionion
depend
avail
relev
clinic
sampl
easili
obtain
clinic
sampl
blood
urin
may
lack
relev
contribut
specif
diagnosi
especi
deepseat
infect
invas
biopsi
often
requir
biopsi
costli
riski
anesthesia
danger
surgeri
prone
incorrect
sampl
limit
tip
biopsi
needl
well
lead
introduct
artifact
contamin
molecular
imag
techniqu
detect
crucial
biolog
biochem
chang
site
infect
often
earliest
phase
diseas
therebi
allow
clinician
promptli
identifi
infect
inflammatori
focu
also
class
caus
pathogen
establish
best
therapeut
approach
patient
tomograph
imag
evalu
diseas
process
deep
within
bodi
noninvas
rapidli
moreov
abil
imag
conduct
noninvas
longitudin
assess
individu
fundament
advantag
current
tradit
tool
major
advantag
imag
abil
provid
holist
threedimension
assess
whole
organ
bodi
less
like
limit
sampl
error
corel
well
overal
diseas
process
tabl
select
recent
exampl
highlight
uniqu
role
imag
infecti
diseas
briefli
describ
overview
optic
imag
method
use
extens
studi
diseas
pathogenesi
larg
small
laboratori
anim
exampl
realtim
analysi
mycobacterium
marinum
infect
transpar
zebrafish
provid
new
insight
tempor
kinet
hostpathogen
interact
similarli
immun
respons
central
nervou
system
cn
viral
infect
visual
real
time
use
intravit
twophoton
laser
scan
microscopi
highli
sensit
optic
imag
limit
depth
signal
therefor
well
suit
studi
laboratori
anim
model
limit
clinic
util
limit
depth
penetr
signal
problem
use
nuclear
medicin
tool
exampl
f
fluorodglucos
f
fdg
positron
emiss
tomographi
pet
comput
tomographi
ct
use
monitor
spatial
evolut
individu
pulmonari
lesion
cohort
infect
mice
develop
tb
lesion
akin
human
studi
tempor
evolut
reactiv
pulmonari
tb
relaps
note
fate
individu
pulmonari
lesion
anim
vari
substanti
interestingli
sever
lesion
also
aros
de
novo
within
region
prior
lesion
suggest
dormant
bacteria
may
also
resid
outsid
tb
lesion
similar
variabl
tb
lesion
within
host
also
report
nonhuman
primat
molecular
imag
therefor
provid
uniqu
insight
diseas
pathogenesi
possibl
tradit
tool
applic
includ
assess
hideout
infect
defin
divers
microbi
popul
microbiom
provid
end
point
assess
antimicrobi
vaccin
efficaci
predict
stabl
cure
current
antimicrobi
dose
regimen
base
achiev
serum
concentr
howev
grow
number
studi
support
import
monitor
drug
concentr
tabl
evalu
diseas
process
deep
within
bodi
noninvas
rel
rapidli
longitudin
assess
individualfundament
advantag
tradit
tool
provid
holist
threedimension
assess
whole
organ
bodi
repres
overal
diseas
versu
tip
biopsi
needl
therefor
less
prone
sampl
error
imag
infecti
diseas
role
set
overal
goal
pathogenesi
preclin
uniqu
insight
diseas
pathogenesi
eg
assess
hideout
infect
defin
divers
microbi
popul
microbiom
studi
multicompart
antimicrobi
pharmacokinet
expedit
benchtobedsid
translat
new
therapeut
eg
surrog
end
point
assess
antimicrobi
vaccin
efficaci
predict
stabl
cure
clinic
trial
uniqu
insight
diseas
pathogenesisnoninvas
visual
process
deep
insid
bodi
phase
studi
determin
compartmentspecif
antimicrobi
penetrationbind
site
infect
necroticfibrot
lesion
privileg
sitescn
inform
appropri
dose
novel
drug
determin
accumul
nontarget
site
assess
potenti
toxic
current
us
food
drug
administr
fda
guidelin
requir
tissu
drug
distribut
studi
infect
site
patient
set
enabl
precis
medicin
provid
uniqu
insight
diseas
pathogenesi
antimicrobi
pharmacokinet
etc
clinic
trial
patient
set
rapidli
specif
distinguish
infecti
process
diseas
malign
steril
inflammatori
process
etc
determin
site
eg
extensionmetastasi
organ
privileg
site
extent
diseas
provid
inform
class
infecti
pathogen
could
help
target
empir
antimicrobi
treatment
monitor
prognost
preclin
noninvas
longitudin
assess
especi
studi
util
larger
expens
anim
speci
serial
assess
anim
could
significantli
reduc
sampl
size
interanim
variabl
outbre
anim
therefor
cost
studi
clinic
trial
earli
end
point
treatment
trial
assess
activ
treatment
predict
stabl
cure
assess
hostdirect
treatment
infect
enabl
adapt
design
patient
set
rapidli
detect
treatment
failur
due
drugresist
organ
reason
rapidli
monitor
treatment
respons
patient
drugresist
organ
individu
treatment
earli
end
point
durat
treatment
predict
stabl
cure
enabl
precis
medicin
public
health
rapid
determin
infecti
risk
patient
popul
base
respons
treatment
extent
locat
diseas
rapid
diagnosi
monitor
biothreat
agent
infect
tissu
rather
serum
alon
inadequ
drug
concentr
target
tissu
lead
treatment
failur
select
drugresist
organ
addit
alter
metabol
diseas
state
may
lead
organ
toxic
vancomycin
wide
use
antimicrobi
treat
drugresist
gramposit
bacteria
highlight
limit
studi
perform
respons
treatment
failur
note
patient
standard
dose
vancomycin
reveal
penetr
poorli
infect
tissu
level
one
sixth
plasma
convers
high
level
vancomycin
caus
nephrotox
base
data
new
recommend
develop
vancomycin
unfortun
inappropri
underdos
decad
noninvas
bioimag
use
assess
distribut
drug
multipl
compart
interest
simultan
exampl
given
import
rifampin
success
cure
potenti
shorten
durat
tb
treatment
limit
avail
situ
data
dynam
pet
imag
perform
min
inject
crifampin
live
tuberculosisinfect
mice
crifampin
rapidli
distribut
quickli
local
liver
area
concentrationtim
curv
first
min
auc
infect
uninfect
mice
uniformli
low
brain
blood
valu
howev
lower
concentr
note
necrot
lung
tissu
infect
mice
healthi
lung
demonstr
need
higher
dose
determin
serum
level
alon
ideal
imag
agent
diagnos
infect
need
sensit
specif
current
noninvas
techniqu
ct
magnet
reson
imag
mri
ultrasound
rapidli
detect
anatom
patholog
nonspecif
reliabl
differenti
infecti
lesion
noninfecti
process
cancer
autoimmun
diseas
similarli
highli
sensit
current
nuclear
imag
tool
oxinetag
white
blood
cell
singlephoton
emiss
comput
tomographi
spect
f
fdg
pet
increasingli
use
infect
nonspecif
final
imag
tool
depend
upon
host
respons
could
alter
immunosuppress
state
eg
cancer
aid
radiolabel
antibiot
antimicrobi
peptid
previous
test
pathogenspecif
imag
tracer
howev
radiolabel
antibiot
demonstr
variabl
specif
inabl
reliabl
differenti
infect
steril
inflamm
radiolabel
peptid
lack
mechanist
bind
uptak
recent
pet
tracer
may
show
promis
tracer
target
pathogenspecif
metabol
process
also
evalu
preclin
studi
fiau
nucleosid
analog
substrat
thymidin
kinas
develop
bacteriaspecif
tracer
later
found
lack
specif
presum
due
host
mitochondri
metabol
pet
could
specif
detect
enterobacteriacea
vivo
variou
differ
site
includ
brain
pet
signal
affect
immunosuppress
cancer
treatment
analog
trehalos
also
develop
potenti
imag
agent
mycobacteria
aspergillu
fumigatu
imag
vivo
use
siderophor
investig
also
util
radiolabel
antibodi
imag
fumigatu
yersinia
murin
model
similarli
santangelo
et
al
develop
techniqu
imag
simian
immunodefici
viru
siv
replic
use
siv
antibodi
abl
detect
virusspecif
pet
signal
treat
untreat
monkey
approach
util
oligom
specif
target
ribosom
rna
pathogen
final
use
endogen
cest
contrast
liu
et
al
abl
imag
bacteriaspecif
mri
signal
c
novyintinfect
tumor
mice
noninvas
imag
includ
nonspecif
agent
use
monitor
diseas
serial
imag
use
assess
antimicrobi
treatment
anim
human
exampl
phase
iii
tb
trial
entail
treat
hundr
patient
month
monitor
year
thereaft
relaps
tuberculosi
infect
part
lung
extrapulmonari
site
tradit
tool
sputum
cultur
naa
eg
mtbrif
alway
correl
overal
diseas
burden
recent
chen
et
al
report
f
fdg
pet
ct
imag
superior
tradit
sputum
microbiolog
monitor
respons
treatment
adult
mdrtb
studi
quantit
chang
lesion
volum
ct
imag
predict
treatment
respons
moreov
quantit
chang
f
fdg
pet
correl
treatment
respons
also
predict
longterm
treatment
outcom
anoth
recent
studi
given
absenc
clinic
microbiolog
marker
diseas
lowradi
exposur
pulmonari
ct
imag
success
use
monitor
treatment
respons
child
xdrtb
guid
individu
drug
regimen
imag
agent
higher
specif
tbassoci
inflamm
shown
promis
anim
model
pathogenspecif
imag
could
even
better
predictor
treatment
respons
exampl
flabel
maltohexaos
f
fd
pet
could
rapidli
identifi
therapeut
failur
associ
drugresist
infect
given
sever
infecti
agent
easili
transmiss
eg
via
aerosol
imag
could
also
help
rapid
determin
infecti
risk
patient
popul
could
especi
relev
highli
drugresist
organ
biothreat
agent
rapid
diagnosi
therapeut
monitor
would
critic
prevent
spread
other
commun
larg
major
infecti
pathogen
handl
use
standard
precaut
howev
anim
infect
pathogen
design
biosafeti
level
requir
appropri
contain
addit
work
biothreat
pathogen
requir
regulatori
approv
well
highli
train
personnel
achiev
contain
sever
group
instal
imag
equip
insid
barrier
eg
niaid
univers
pittsburg
advantag
maintain
expens
equip
within
barrier
complic
therefor
group
util
anim
isol
approach
achiev
isol
infectedanim
insid
seal
biocontain
devic
transport
imag
equip
hous
standard
environ
polycarbon
plastic
tube
extend
biocontain
space
imag
equip
tail
vein
cathet
system
also
use
ontabl
drug
deliveri
infect
anim
seal
insid
biocontain
devic
anim
contain
allow
easier
mainten
equip
also
share
investig
work
within
barrier
unlik
tradit
microbiolog
molecular
techniqu
imag
provid
key
spatial
inform
dictat
treatment
enabl
detect
therapeut
monitor
infect
patient
deepseat
infect
tradit
clinic
sampl
eg
blood
urin
would
insensit
high
risk
impract
eg
biopsi
brain
infect
rapid
assess
therapeut
effect
need
fact
clinic
practic
john
hopkin
hospit
oncolog
patient
fever
neutropenia
patient
fever
unknown
origin
fuo
routin
undergo
whole
bodi
imag
look
foci
fig
rel
risk
infect
treatmentand
radiationinduc
cancer
risk
mortal
due
infect
tb
exampl
compar
risk
radiationinduc
cancer
due
commonli
use
imag
techniqu
risk
mortal
mdrand
xdrtb
patient
treatment
similar
due
cancer
even
drugsuscept
tb
patient
treatment
significantli
higher
risk
mortal
radiationinduc
cancer
optim
imag
risk
radiationinduc
cancer
mortal
theoret
estim
base
acut
radiat
exposur
msv
actual
risk
like
much
lower
smaller
amount
radiat
infect
howev
current
imag
modal
specif
biopsi
often
nondiagnost
lead
uncertainti
overus
misus
broadspectrum
antimicrobi
ct
nuclear
medicin
techniqu
often
perceiv
deliv
high
level
radiat
howev
recent
technolog
develop
significantli
lower
radiat
exposur
also
allow
rapid
scan
avoid
need
sedat
children
exampl
effect
dose
chest
ct
child
treat
xdrtb
msv
equival
month
natur
background
radiat
singl
screen
mammographi
four
transatlant
airplan
round
trip
moreov
sedat
requir
child
scan
time
short
calcul
risk
relat
infect
tb
exampl
compar
variou
imag
techniqu
use
current
fig
risk
mortal
patient
mdrand
xdrtb
treatment
similar
due
cancer
moreov
even
patient
drugsuscept
tb
treatment
sever
order
magnitud
higher
risk
mortal
theoret
risk
due
radiationinduc
cancer
develop
nuclear
imag
tracer
short
halflif
isotop
rapid
elimin
bodi
could
limit
radiat
exposur
studi
perform
without
excel
rational
clinic
indic
need
pragmat
minim
risk
imag
especi
deal
infect
due
mdr
organ
given
subpharmacolog
dose
sever
approach
translat
pet
tracer
human
allow
rapid
translat
new
imag
tool
clinic
pet
tracer
discuss
current
test
human
recent
studi
healthi
volunt
demonstr
ffd
safe
well
toler
rapidli
clear
follow
singl
intraven
dose
suggest
signific
potenti
use
human
past
decad
develop
countri
especi
bric
nation
brazil
russia
india
china
south
africa
wit
signific
increas
instal
use
advanc
imag
exampl
new
delhi
india
alon
clinic
mri
scanner
sever
strength
moreov
ct
mri
petct
cost
substanti
lower
ct
mri
pet
per
scan
privat
forprofit
center
develop
nation
india
usa
mobil
pet
scanner
ga
pet
agent
gener
without
need
cyclotron
hold
great
promis
use
remot
area
china
alreadi
overtaken
usa
becom
largest
economi
purchas
power
pariti
india
expect
becom
second
largest
economi
purchas
power
pariti
infect
rampant
develop
world
given
consider
number
peopl
live
big
citi
advanc
imag
potenti
becom
power
routin
clinic
tool
earli
diagnosi
monitor
infecti
diseas
develop
countri
acknowledg
would
like
thank
mahesh
chief
physicistjohn
hopkin
hospit
review
data
radiat
risk
relat
imag
techniqu
fund
review
fund
nation
institut
health
nih
director
transform
research
award
skj
skj
well
nih
director
new
innov
award
skj
funder
role
review
design
decis
publish
prepar
manuscript
